Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...
Morgan Stanley raised the firm’s price target on Vertex (VERX) to $60 from $57 and keeps an Overweight rating on the shares. The company’s ...
Vertex, Inc. (NASDAQ: VERX) today announced that it will host an Investor Day on Wednesday, March 19, in Philadelphia, PA.
There’s a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Vertex (VERX – Research Report) and AppLovin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback